LY2495655, an antimyostatin antibody in pancreatic cancer: a randomized phase 2 trial

LY2495655, an antimyostatin antibody in pancreatic cancer: a randomized phase 2 trial

Background: Cachexia is a formidable clinical challenge in pancreatic cancer. We assessed LY2495655 (antimyostatin antibody) plus standard-of-care chemotherapy in pancreatic cancer using cachexia status as a stratifier. Methods: In this randomized, phase 2 trial, patients with stage II-IV pancre...

Full description

Bibliographic Details
Main Authors: Golan, Talia, Geva, Ravit, Richards, Donald, Madhusudan, Srinivasan, Lin, Boris Kin, Wang, Haofei Tiffany, Walgren, Richard A., Stemmer, Salomon M.
Format: Article
Published: Wiley 2018
Subjects:
Myostatin; Cachexia; Pancreatic cancer; Muscle mass
Online Access:https://eprints.nottingham.ac.uk/52403/

Internet

https://eprints.nottingham.ac.uk/52403/

Similar Items